“This enactment amends the Controlled Drugs and Substances Act to provide for minimum penalties for serious drug offences, to increase the maximum penalty for cannabis (marihuana) production and to reschedule certain substances from Schedule III to that Act to Schedule I.” [From the Bill’s summary page.]
This bill is similar to Bill C-15, which almost made it through the previous session—until Prime Minister Harper prorogued parliament and killed the bill. I guess deep down he’s soft on crime.
Third time lucky? Let’s hope not.
“This enactment amends the Controlled Drugs and Substances Act to provide for minimum penalties for serious drug offences, to increase the maximum penalty for cannabis (marihuana) production and to reschedule certain substances from Schedule III to that Act to Schedule I.” [From the Bill’s summary page.]
This bill is similar to Bill C-26, tabled but not passed in the previous parliament. This bill passed both the house and the senate (with amendments). But it was all for naught; the Bill was doomed when the 2nd Session of the 40th Parliament was prorogued 30 Dec 2009.
“This notice provides interested stakeholders with the opportunity to provide preliminary comments on Health Canada’s proposal to add a series of benzyl/phenyl piperazine derivatives to the schedules to the Controlled Drugs and Substances Act (CDSA), and to identify themselves for inclusion in any future consultation.”
The substances under consideration are
“This enactment amends the Controlled Drugs and Substances Act to provide for minimum penalties for serious drug offences, to increase the maximum penalty for cannabis (marihuana) production, to reschedule certain substances from Schedule III to that Act to Schedule I, and to make consequential amendments to other Acts.” [From the Bill’s summary page.]
This bill died when the 39th parliament was dissolved 7 Sept 2008.
A response to concerns raised by the Standing Joint Committee for the Scrutiny of Regulations (SJCSR) regarding inconsistencies between the English and French versions, and non-substantive clarifications of certain provisions.
Health Canada proposes adding Tramadol to Schedule I of the CDSA.
“This enactment amends the Controlled Drugs and Substances Act to prohibit the production, possession and sale of any substance or any equipment or other material that is intended for use in production of or trafficking in methamphetamine.” [From the Bill’s summary page.]
This bill died when the 39th parliament was dissolved 7 Sept 2008.
This amendment implements changes proposed in C. Gaz. 2005.I.2111.
Six additional “precursor” chemicals are added to Schedule VI of the CDSA, as proposed earlier in C. Gaz. 2005.I.2098.
The Schedule I entry for Methamphetamine is expanded to include “its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues.”
This amendment clarifies and corrects the situation created when Methamphetamine was moved, perhaps too hastily, to Schedule I from Schedule III by SOR/2005-235.
Ketamine is added to the Narcotic Control Regulations in line with its addition to Schedule I of the CDSA by SOR/2005-271.
Ketamine is formally added to Schedule I of the CDSA.
There was no formal advance notice of this amendment in the Canada Gazette, Part I. However, Health Canada did signal their interest in Ketamine in C. Gaz. 2004.I.204, and later declared (in Status of Ketamine under the CDSA) that Ketamine shall be considered “an analogue” of Phencyclidine, a Schedule I substance.
Ketamine is removed from the Food and Drug Regulations in line with its addition to Schedule I of the CDSA (see also SOR/2005-271 above).
Methamphetamine moves to Schedule I from Schedule III.
Interestingly, in its former Schedule III location, the entry for Methamphetamine included “salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues.” Its current location in Schedule I names only the unadorned free base.
While I doubt it was the intent of this amendment, it seems to me that, for example, salts such as Methamphetamine hydrochloride, are no longer captured by the CDSA.
See C. Gaz. 2005.I.2098 below.
“The purpose of this proposed initiative is to amend Schedule VI to the Controlled Drugs and Substances Act (CDSA) and the Precursor Control Regulations (PCR) to strengthen the regulatory framework and minimize any negative impact of the Regulations on the legitimate trade of precursors.
“Among other things, the proposed amendments will add six substances to the CDSA and the PCR: Gamma-butyrolactone (GBL), 1,4-Butanediol (BDO), Red phosphorus, White phosphorus, Hypophosphorous acid, and Hydriodic acid.” [From the Regulatory Impact Analysis Statement (RIAS).]
Health Canada now considers Ketamine to be an analogue of Phencyclidine, a Schedule I substance.
“Analogue,” as defined by the CDSA, means “a substance that, in relation to a controlled substance, has a substantially similar chemical structure.” The CDSA provides no definition for “substantially similar.”
This bill is similar to Bill C-10, tabled but not passed in the previous session of parliament.
This bill died when the 38th parliament was dissolved 29 Nov 2005.
This bill is similar to Bill C-38, tabled but not passed in the previous session of parliament.
This bill died when the 3rd session of the 37th parliament ended 23 May 2004.
Health Canada proposes to add Ketamine to the CDSA.
Amineptine is added to Schedule III of CDSA.
Health Canada proposes to add Red Phosphorous and White Phosphorous to the CDSA.
Health Canada proposes to add Gamma-butyrolactone (GBL) and 1,4-Butanediol (BDO) to the CDSA.
“The enactment amends the Contraventions Act to allow for the designation of certain criminal offences as contraventions and to specify that contraventions may be prosecuted by means of either a summons or ticket unless another Act of Parliament provides otherwise.
“The enactment also amends the Controlled Drugs and Substances Act to create offences with respect to the possession of small amounts of cannabis (marihuana) and the production of cannabis (marihuana).”
[From the Bill’s summary page.]
This bill died when the 2nd session of the 37th parliament ended 12 Nov 2003.
Health Canada corrects errors introduced by SOR/97-230 and identified by the Standing Joint Committee for the Scrutiny of Regulations, in the CDSA entries for Levargorphan and Clotiazepam.
Health Canda adds Remifentanil and Olanzapine to the CDSA, and excludes Nalmefene and Naltrexone from the CDSA.
Health Canda proposes to add Remifentanil and Olanzapine to the CDSA, and to exclude Nalmefene and Naltrexone from the CDSA.
“The amendments to the Controlled Drugs and Substances Act in this enactment deal with aggravating factors in sentencing and the criminal liability of law enforcement officers engaged in their duties.” [From the Bill’s summary page.]
Notice of proposed scheduling of Remifentanil, Nalmefene, Olanzapine and Naltrexone.
Notice of a review of the regulations pertaining to benzodiazepines and other targeted substances.
“An Act respecting the control of certain drugs, their precursors and other substances and to amend certain other Acts and repeal the Narcotic Control Act in consequence thereof.” [From the Bill’s summary page.]
Page updated 11 July 2010 · Copyright © 2010 
